Oncogenic-Directed Therapy for Advanced Non-Small Cell Lung Cancer: Implications for the Advanced Practice Nurse

Area of Science:

• Oncology
• Molecular Diagnostics
• Personalized Medicine

Background:

• Molecular profiling for oncogenic driver mutations is critical for diagnosing advanced non-small cell lung cancer (NSCLC).
• Identifying these mutations enables personalized targeted therapy, improving patient outcomes.
• Advanced practice nurses (APNs) are central to coordinating NSCLC patient care.

Purpose of the Study:

• To emphasize the importance of molecular profiling in advanced NSCLC diagnosis.
• To highlight the role of APNs in ensuring appropriate molecular testing and targeted therapy selection.
• To underscore the integration of molecular diagnostics into the continuum of NSCLC care.

Main Methods:

• Review of current diagnostic and therapeutic standards for advanced NSCLC.
• Analysis of the role of molecular profiling in guiding treatment decisions.
• Examination of the responsibilities of advanced practice nurses in NSCLC management.

Main Results:

• Molecular profiling accurately identifies actionable oncogenic drivers in NSCLC.
• Test results directly inform the selection of personalized targeted therapies.
• APNs are pivotal in facilitating comprehensive molecular testing and subsequent treatment planning.

Conclusions:

• Molecular profiling is indispensable for personalized treatment of advanced NSCLC.
• APNs are essential members of the multidisciplinary team, ensuring optimal utilization of molecular testing.
• Effective coordination by APNs ensures patients receive timely and appropriate targeted therapies based on genetic profiles.